Addendum
Osimertinib (lung cancer) - Addendum to Commission A17-20
Report documents
-
Addendum
Osimertinib (lung cancer) - Addendum to Commission A17-20
Dossier assessment
Indication:
Advanced NSCLC (lung cancer) with T790M mutation after pretreatment with EGFR-TKI
Result of dossier assessment:
Unchanged hint of non-quantifiable, at least considerable added benefit versus cisplatin + pemetrexed
Additional information
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.
Project details
- Project no.
- A17-47
- Commission
- Commission awarded on 12.09.2017 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed